Biologics & Biotechnology
Enhancing Safety and Sustainability in Therapeutics and Food Production
In addition to the development and manufacturing of animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements catering to the needs of Stem Cells and Regenerative Medicine, Vaccines and Biological Drugs, Cultured Meat, and Cell-Culture Media Manufacturing, Laurus Bio, a subsidiary of Laurus Labs, extends its expertise in precision fermentation as a Contract Development and Manufacturing Organization (CDMO) service. This service is offered to novel protein companies and bio-manufacturers operating across healthcare, food, nutrition, personal care, and bio-based materials markets.
In addition to developing & manufacturing animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements that cater to the needs of Stem Cells and Regenerative Medicine, Vaccines and Biological Drugs, Cultured Meat, and Cell-Culture Media Manufacturing etc., Laurus Bio, a subsidiary of Laurus Labs, also offers precision fermentation expertise as a CDMO service to novel protein companies and bio-manufacturers across healthcare, food, nutrition, personal care, and bio-based materials markets.
Bio-Manufacturing
Laurus Bio, a subsidiary of Laurus Labs, also offers precision fermentation expertise as a CDMO service to novel protein companies and bio-manufacturers across healthcare, food, nutrition, personal care, and bio-based materials markets.
Infrastructure
Capabilities
2
Manufacturing sites in Bangalore with microbial fermentation capacity of 210 Kilo Liters
300+
Team of highly qualified and experienced scientists & bioengineers
45
Expertise in manufacturing small organic molecules as well as biomolecules such as proteins and enzymes
45
Expertise in manufacturing small organic molecules as well as biomolecules such as proteins and enzymes
Commitment to the highest regulatory and quality standards: ISO | Halal | Kosher | GMP | FSSC certified
2
Manufacturing sites in Bangalore with microbial fermentation capacity of 210 Kilo Liters
300+
Team of highly qualified and experienced scientists & bioengineers
45
Expertise in manufacturing small organic molecules as well as biomolecules such as proteins and enzymes
45
Expertise in manufacturing small organic molecules as well as biomolecules such as proteins and enzymes
Commitment to the highest regulatory and quality standards: ISO | Halal | Kosher | GMP | FSSC certified
Solutions
Integrated Microbial Precision Fermentation Solution
The Integrated Microbial Precision Fermentation Solution offered by Laurus Bio encompasses various aspects, including clone development, strain engineering, process development, and scale-up. This comprehensive solution is designed to facilitate large-scale commercial manufacturing of protein entities such as enzymes and growth factors.
Standalone Microbial Precision Fermentation Solution
The Standalone Microbial Precision Fermentation Solution provided by Laurus Bio involves key components such as tech-transfer in, process optimization, and the scale-up process. This solution is specifically tailored for large-scale commercial manufacturing of protein entities, including enzymes and growth factors, ensuring efficient and optimized production processes.
Products
Click here for our Product List.
Advancing Cell & Gene Therapy
Vision
While maintaining its leadership in small-molecule therapeutics, Laurus Labs acknowledges the significance of bringing forth accessible Cell and Gene Therapy treatment technologies.
These advanced therapies, often financially out of reach for many patients, are a key focus for Laurus Labs. Over the past 2+ years, strategic investments and collaborations with ImmunoACT and IIT-Kanpur underscore Laurus Labs' commitment to making Cell and Gene Therapy treatments more affordable, especially for patients in unmet medical need segments such as auto-immune diseases and oncology.. This venture into Cell and Gene technologies synergizes with and enhances Laurus's Biologics initiatives through Laurus Bio.
These advanced therapies, often financially out of reach for many patients, are a key focus for Laurus Labs. Over the past 2+ years, strategic investments and collaborations with ImmunoACT and IIT-Kanpur underscore Laurus Labs' commitment to making Cell and Gene Therapy treatments more affordable, especially for patients in unmet medical need segments such as auto-immune diseases and oncology.. This venture into Cell and Gene technologies synergizes with and enhances Laurus's Biologics initiatives through Laurus Bio.
Collaborations
Immuno-adoptive Cell Therapy Private Limited (ImmunoACT) stands as a trailblazer in Cell and Gene Therapy. Currently on the verge of becoming India’s first company to introduce CART therapy for specific types of Blood Cancers undergoing Clinical Trials, ImmunoACT benefits from Laurus Labs' investments in 2021 and again in 2023. These investments aim to empower ImmunoACT to accelerate clinical evaluations of its therapies, expediting access to a wider patient population.
The Department of Biological Sciences and Bioengineering (BSBE) at IIT Kanpur has been actively engaged in gene therapy research for several years, resulting in the development of various gene therapy assets and cutting-edge technology for novel Adeno-Associated Virus (AAV) vectors. Their innovative work has led to the filing of intellectual property (IP) rights and the anticipation of additional patent applications in the near future.
Through its strategic partnership with IIT Kanpur, Laurus Labs aims to fortify its position in the promising Cell and Gene Therapy (CGT) space, aspiring to emerge as a leader in this field. Notably, these advanced therapies are currently unavailable in India and other emerging markets. The collaboration holds the promise of making these novel therapies accessible to Indian patients at affordable prices, marking a significant stride toward addressing unmet medical needs.